Background and Aims: For patients with resectable lung cancer less than 2 cm in poor condition such as heart and/or lung dysfunction, segmentectomy may be another alternative option, when no metastasis of the N1 and N2 lymph nodes was confirmed. Frozen section is widely used for rapid diagnosis, but it takes too much time of waiting and its accuracy depends on the pathologists. On the other hand, dielectric property has been proven to be objective and vary among different tissues under different pathophysiological conditions. In this way, this studies aims to investigate the accuracy of dielectric property test in the rapid diagnosis of thoracic lymph nodes metastasis.
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Methods:
Patients with lung cancer receiving surgery with lymph nodes dissection were recruited. Lymph nodes were tested for dielectric property immediately after dissection before sending to pathologist for frozen section diagnosis, which takes less than 5 min. The informed consents were obtained before surgery. Mann-Whitney Test and multiple variables for ROC curve analysis were used.
Results: 159 thoracic lymph nodes from 51 patients with lung cancer were tested. And according to pathological diagnosis, no metastasis were found in 128 lymph nodes, while metastasis were found in the other 31. For each node, 4000 datasets of dielectric property (permittivity and conductivity) at different frequencies from 1 MHz to 4000 MHz were collected. The differences of mean permittivity and conductivity between the 2 groups were both statistically significant (P<0.001). The AUC of ROC curve with permittivity was 0.917(95% CI: 0.872-0.961), the AUC with conductivity was 0.853(95% CI: 0.776-0.931), and the AUC with the joint of permittivity and conductivity was 0.926 (95% CI: 0.886-0.966). Background and Aims Background: Anti-PD-L1 antibody (atezolizumab) was approved for non-small cell lung cancer (NSCLC). Physician can use anti-PD-L1 antibody (atezolizumab) in addition to anti-PD-1 antibodies (nivolumab and pembrolizumab) for the treatment of NSCLC. It is still unclear that efficacy and safety of using anti-PD-L1 antibody for the patients who previously treated with anti-PD-1 antibodies.
Conclusion
Aim: To investigate the efficacy and safety of atezolizumab for the patients who previously treated with nivolumab and/or pembrolizumab.
Methods: We retrospectively reviewed the NSCLC patients who treated with atezolizumab after receiving nivolumab and/or pembrolizumab during the treatment of lung cancer.
Results: Total 14 patients were received atezolizumab for the treatment. Of 14 patients, 9 (64.3%) patients received at least one anti-PD-1 antibody (nivolumab and/or pembrolizumab) treatment. These patients were mean age at 71.6 AE 6.7 year-old. Four (44.4%) patients had adenocarcinoma, 3 (33.3%) patients had squamous cell carcinoma, a (11.1%) patient had adeno-squamous cell carcinoma and a (11.1%) patient had NOS, respectively. PD-L1 expression of the tumor tissues showed TPS 50%≤ for 4 (44.4%) patients, 1% ≤ TPS < 50% for 2 (22.2%) patients, TPS < 1% for a (11.1%) patient and undetermined for 2 (22.2%) patients, respectively. Median regimens before atezolizumab were three. Patients who received cytotoxic chemotherapy between anti-PD-1 antibody and atezolizumab were five (55.6%). Two patients (22.2%) maintained their best response as stable disease and partial response.
Conclusion Conclusions: Total 9 patients received atezolizumab after the treatment with anti-PD-1 antibodies (nivolumab and/or pembrolizumab). Only selected patients could receive the benefits of atezolizumab after anti-PD-1 antibodies therapy in our preliminary study.
